One Firm's Focus Permits Another's Expansion
Executive SummarySangStat Medical, a Menlo Park CA-based firm applying a disease-management approach to organ transplantation, announced in mid-April that it would acquire Imtix, the transplant-focused business unit of Pasteur Merieux Connaught. If the deal goes through, SangStat will have itself a turn-key European marketing operation, ready and able to sell Sang-35, its own formulation of anti-organ rejection drug cyclosporine.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.